The company had posted net profit of Rs 239.19 crore for the January-March quarter of the previous fiscal, Cadila Healthcare said in a filing to BSE.
Consolidated total income of the company rose to Rs 2,288.23 crore for the fourth quarter of 2014-15 from Rs 1,968.50 crore for the same period a year ago.
The company posted consolidated net profit of Rs 1,150.59 crore for the last fiscal as against Rs 803.59 crore for in 2013-14.
Its income for the entire financial year ended March this year rose to Rs 8,651.34 crore. It was Rs 7,224.03 crore for the previous fiscal.
In another filing to BSE, Cadila Healthcare said its Board of Directors have recommended a dividend of Rs 12 per equity share on 204,748,520 equity shares of Rs 5 on March 31, 2015.
"During the year, the group filed 38 ANDAs with the US Food and Drug Administration (USFDA), taking the cumulative filings to 260. The group received 8 ANDA approvals during the year taking the total to 99 product approvals," Cadila Healthcare said.
Cadila Healthcare stock was trading at Rs 1,710.90, up 3.18 per cent, on BSE.